Dec. 28, 2024: cosibelimab Checkpoint Therapeutics resubmitted an application for its anti-programmed death ligand-1 (PD-L1) antibody, cosibelimab, for the treatment for adults with metastatic or...

Publications Clinical Highlights: April 2025 Your monthly source for drug information highlights. Shortage updates The U.S. Government Accountability Office (GAO) has published a report on drug...

cover image Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-november-2025 Prime Therapeutics’ Cell & Gene Pipeline Outlook is an industry report that...

U.S. News & World Report